Barclays lowered the firm’s price target on AnaptysBio (ANAB) to $70 from $83 and keeps an Overweight rating on the shares. The firm says the pathogenic T-cell depletion did not translate to a benefit in ulcerative colitis. It cites the discontinuation of rosnilimab development in ulcerative colitis for the target cut.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB: